1 week Ago By ABMN Staff
Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS – Get Free Report ) has earned an average recommendation of “Buy” from the five research firms that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company.
The average 12 month target price among brokers that have issued ratings on the stock in the last year is $12.38. A number of research firms have commented on CRVS.
Oppenheimer boosted their price target on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th.
StockNews.com lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd.
LADENBURG THALM/SH SH upped their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th.
Finally, HC Wainwright initiated coverage on shares of Corvus Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $11.00 target price for the company.
Read Our Latest Stock Report on Corvus Pharmaceuticals Corvus Pharmaceuticals Price Performance Hedge Funds Weigh In On Corvus Pharmaceuticals Several institutional investors have recently added to or reduced their stakes in CRVS. Cubist Systematic Strategies LLC bought a new stake in shares of Corvus Pharmaceuticals during the second quarter worth $44,000. Nwam LLC acquired a new stake in Corvus Pharmaceuticals in the 3rd quarter valued at about $53,000.
XTX Topco Ltd acquired a new position in shares of Corvus Pharmaceuticals during the third quarter worth approximately $74,000. Virtu Financial LLC acquired a new position in Corvus Pharmaceuticals during the 3rd quarter worth $83,000. Finally, Oppenheimer & Co.
Inc. bought a new position in Corvus Pharmaceuticals in the 3rd quarter valued at $89,000. 46.
64% of the stock is owned by institutional investors. Corvus Pharmaceuticals Company Profile ( Get Free Report Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Recommended Stories Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
